Compare NDAQ & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NDAQ | TEVA |
|---|---|---|
| Founded | 1971 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9B | 40.5B |
| IPO Year | 2001 | 1996 |
| Metric | NDAQ | TEVA |
|---|---|---|
| Price | $33.00 | $37.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $105.62 | $38.63 |
| AVG Volume (30 Days) | 2.7M | ★ 5.5M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | 60.10 | ★ 183.45 |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $4,277,000,000.00 | N/A |
| Revenue This Year | $10.52 | N/A |
| Revenue Next Year | $8.17 | $2.97 |
| P/E Ratio | $54.95 | ★ N/A |
| Revenue Growth | ★ 7.87 | N/A |
| 52 Week Low | $76.55 | $17.89 |
| 52 Week High | $101.79 | $37.83 |
| Indicator | NDAQ | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 63.94 |
| Support Level | $96.47 | $30.42 |
| Resistance Level | $101.50 | N/A |
| Average True Range (ATR) | 1.75 | 0.82 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 81.07 | 84.49 |
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.